

**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
666 FIFTH AVENUE, 31ST FLOOR  
NEW YORK, NEW YORK 10103-3198  
WWW.FULBRIGHT.COM

**FACSIMILE TRANSMISSION**

**DATE:** March 11, 2003

**MATTER NUMBER:**

09905230

RECIPIENT(S):	FAX NO.:	PHONE NO.:
Examiner G. Nichol USPTO, Group 1643	703-305-7230	

**FAX RECEIVED**

MAR 13 2003

GROUP 1600

**OFFICIAL**

**FROM:** Norman Hanson **USER ID:** N1101030 **FLOOR:** 24

**PHONE:** (212) 318-3168 **FAX:** (212) 318-3400

**RE:** LUD 5615

**NUMBER OF PAGES WITH COVER PAGE:** 4

**Message:**

**CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL  
AT \_\_\_\_\_ AS SOON AS POSSIBLE.**

VIA FAX/SIMILE

I hereby certify that this correspondence is being facsimile transmitted to  
Commissioner of Patents and Trademarks, Washington, D.C. 20231 on March  
11, 2003

Fulbright &amp; Jaworski L.L.P.

*[Signature]*

LUD S. (09905230)-NDH

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	JAGER, et al.
Serial No.	:	09/451,739
Filed	:	November 30, 1999
For	:	ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODING CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE, AND USES THEREOF
Group Art Unit	:	1643
Examiner	:	G. Nichol

March 11, 2003

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**RESPONSE TO  
RESTRICTION REQUIREMENT**

Responsive to the restriction requirement dated February 14, 2003, applicants elect Group XIII, with traverse. In connection with the traverse, applicants submit the amendment which follows:

**IN THE CLAIMS**

Cancel claims 1-79 without prejudice.

Add claims 80-97 which follow:

*G. Nichol*

Claim 80. An isolated nucleic acid molecule, the complementary sequence of which hybridizes, under stringent conditions, to one of the nucleotide sequences set forth in SEQ ID NO: 4, 8 or 15.

Claim 81. The isolated nucleic acid molecule of claim 80, comprising the nucleotide sequence of SEQ ID NO: 15.

Claim 82. The isolated nucleic acid molecule of claim 80, comprising the nucleotide sequence of SEQ ID NO: 8.

25272605.1